Price Target Adjustment#
Stifel has lowered its price target for Boston Scientific Corp. shares from $90 to $85 while keeping a Buy rating. This adjustment comes just ahead of the company’s first-quarter 2026 earnings report, which is set for April 22, 2026. Currently, the stock is trading at $60.99, close to its 52-week low of $60.59, and has seen a significant decline of 36% year-to-date from its peak of $109.50.
Analysis Based on Electrophysiology Data#
The analyst, Rick Wise, based this price target change on recent monthly data related to electrophysiology (EP) hospital purchases. This data helps predict the company’s performance in the upcoming quarter. For January, about 92% of the data was reported, February saw 85%, and March had around 60% reported. Stifel had previously indicated potential risks to revenue expectations for US EP sales.
Revenue Projections#
According to the data, Boston Scientific’s expected US EP revenues for the first quarter of 2026 are around $587 million, which analysts believe is achievable. This projection is compared to similar data from Johnson & Johnson and Abbott Laboratories, which helps provide context for Boston Scientific’s performance.
Recent Developments#
In other news, Boston Scientific recently announced positive results from its CHAMPION-AF trial for the Watchman heart implant, meeting all primary and secondary safety and efficacy endpoints. However, the device showed a slightly higher rate of ischemic strokes compared to other anticoagulants, which disappointed some investors. Despite this, UBS maintained a Buy rating with a price target of $105, while other firms like Truist Securities and Piper Sandler also kept their positive ratings, indicating mixed but ongoing interest in Boston Scientific’s future prospects.